These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
501 related articles for article (PubMed ID: 15118763)
1. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Chawla-Sarkar M; Bae SI; Reu FJ; Jacobs BS; Lindner DJ; Borden EC Cell Death Differ; 2004 Aug; 11(8):915-23. PubMed ID: 15118763 [TBL] [Abstract][Full Text] [Related]
2. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Ng CP; Zisman A; Bonavida B Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140 [TBL] [Abstract][Full Text] [Related]
3. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. Ravi R; Bedi A Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014 [TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Zhang XD; Zhang XY; Gray CP; Nguyen T; Hersey P Cancer Res; 2001 Oct; 61(19):7339-48. PubMed ID: 11585775 [TBL] [Abstract][Full Text] [Related]
5. Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death. Yamaguchi Y; Shiraki K; Fuke H; Inoue T; Miyashita K; Yamanaka Y; Saitou Y; Sugimoto K; Nakano T Oncol Rep; 2005 Nov; 14(5):1311-6. PubMed ID: 16211302 [TBL] [Abstract][Full Text] [Related]
6. Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Ozören N; El-Deiry WS Neoplasia; 2002; 4(6):551-7. PubMed ID: 12407450 [TBL] [Abstract][Full Text] [Related]
7. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells. Izeradjene K; Douglas L; Delaney A; Houghton JA Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455 [TBL] [Abstract][Full Text] [Related]
8. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis. Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478 [TBL] [Abstract][Full Text] [Related]
9. Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors. Aggarwal BB; Bhardwaj U; Takada Y Vitam Horm; 2004; 67():453-83. PubMed ID: 15110190 [TBL] [Abstract][Full Text] [Related]
10. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells. Mori T; Doi R; Kida A; Nagai K; Kami K; Ito D; Toyoda E; Kawaguchi Y; Uemoto S J Surg Res; 2007 Oct; 142(2):281-6. PubMed ID: 17640673 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of CaMKII-mediated c-FLIP expression sensitizes malignant melanoma cells to TRAIL-induced apoptosis. Xiao C; Yang BF; Song JH; Schulman H; Li L; Hao C Exp Cell Res; 2005 Mar; 304(1):244-55. PubMed ID: 15707589 [TBL] [Abstract][Full Text] [Related]
12. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells. Lane D; Cartier A; L'Espérance S; Côté M; Rancourt C; Piché A Gynecol Oncol; 2004 Jun; 93(3):594-604. PubMed ID: 15196850 [TBL] [Abstract][Full Text] [Related]
13. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation. Rosato RR; Dai Y; Almenara JA; Maggio SC; Grant S Leukemia; 2004 Nov; 18(11):1780-8. PubMed ID: 15385934 [TBL] [Abstract][Full Text] [Related]
14. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation. Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347 [TBL] [Abstract][Full Text] [Related]
15. Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. Kim EH; Kim SU; Choi KS Oncogene; 2005 Jan; 24(5):838-49. PubMed ID: 15531913 [TBL] [Abstract][Full Text] [Related]
16. Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells. Poulaki V; Mitsiades CS; Kotoula V; Tseleni-Balafouta S; Ashkenazi A; Koutras DA; Mitsiades N Am J Pathol; 2002 Aug; 161(2):643-54. PubMed ID: 12163389 [TBL] [Abstract][Full Text] [Related]
17. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin. Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094 [TBL] [Abstract][Full Text] [Related]
18. Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. Kim EH; Kim HS; Kim SU; Noh EJ; Lee JS; Choi KS Oncogene; 2005 Oct; 24(46):6877-89. PubMed ID: 16007142 [TBL] [Abstract][Full Text] [Related]
19. Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells. Lippa MS; Strockbine LD; Le TT; Branstetter DG; Strathdee CA; Holland PM Apoptosis; 2007 Aug; 12(8):1465-78. PubMed ID: 17440816 [TBL] [Abstract][Full Text] [Related]
20. Human soluble TRAIL/Apo2L induces apoptosis in a subpopulation of chemotherapy refractory nodal diffuse large B-cell lymphomas, determined by a highly sensitive in vitro apoptosis assay. Cillessen SA; Meijer CJ; Ossenkoppele GJ; Castricum KC; Westra AH; Niesten P; Muris JJ; Nijdam HF; van der Hem KG; Flens M; Hooijberg E; Oudejans JJ Br J Haematol; 2006 Aug; 134(3):283-93. PubMed ID: 16848771 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]